<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823702</url>
  </required_header>
  <id_info>
    <org_study_id>282-HI-104</org_study_id>
    <nct_id>NCT04823702</nct_id>
  </id_info>
  <brief_title>Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function</brief_title>
  <official_title>A Phase I, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Aldafermin in Subjects With Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group&#xD;
      study in participants with Impaired Hepatic Function&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of a single dose aldafermin</measure>
    <time_frame>4 days</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of aldafermin (Day 1 through Day 4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of a single dose of aldafermin</measure>
    <time_frame>4 days</time_frame>
    <description>Area under the concentration-time curve from time zero extrapolated to infinity (AUC infinity) of aldafermin (Day 1 through Day 4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type and frequency of adverse events (Day 1 through Day 11)</measure>
    <time_frame>11 days</time_frame>
    <description>Frequency, severity, timing, and/or duration of treatment-emergent adverse events (TEAE) and serious adverse events (SAEs)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics (PD) of biomarker 7-alpha-hydroxy-4-cholesten-3-one (C4)</measure>
    <time_frame>6 and 24 hours post dose</time_frame>
    <description>Absolute change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics (PD) of biomarker 7-alpha-hydroxy-4-cholesten-3-one (C4)</measure>
    <time_frame>6 and 24 hours post dose</time_frame>
    <description>Percent change from baseline</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Impaired Hepatic Function</condition>
  <arm_group>
    <arm_group_label>Child-Pugh A (Mild Hepatic Impairment) &amp; Healthy Matched</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Child-Pugh B (Moderate Hepatic Impairment) &amp; Healthy Matched</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Child-Pugh C (Severe Hepatic Impairment) &amp; Healthy Matched</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldafermin</intervention_name>
    <description>Biological: Aldafermin (NGM282) Subcutaneous Injection</description>
    <arm_group_label>Child-Pugh A (Mild Hepatic Impairment) &amp; Healthy Matched</arm_group_label>
    <arm_group_label>Child-Pugh B (Moderate Hepatic Impairment) &amp; Healthy Matched</arm_group_label>
    <arm_group_label>Child-Pugh C (Severe Hepatic Impairment) &amp; Healthy Matched</arm_group_label>
    <other_name>NGM282</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, 18 - 75 years of age, inclusive&#xD;
&#xD;
          2. Able to comprehend and willing to sign an informed consent form (ICF)&#xD;
&#xD;
          3. Willing and able to comply with all study requirements&#xD;
&#xD;
          4. BMI 18 - 40 kg/m2, inclusive at Screening&#xD;
&#xD;
          5. Stable medication regimen - no medication initiation or dose change within 7 days or 5&#xD;
             half-lives (whichever is longer) prior to dosing of the study medication.&#xD;
&#xD;
          6. Non-pregnant, non-lactating females. Female subjects of childbearing potential and&#xD;
             male subjects with a female sexual partner of childbearing potential must agree to&#xD;
             consistent and adequate birth control. One of the following forms of contraception is&#xD;
             required:&#xD;
&#xD;
               1. Condom&#xD;
&#xD;
               2. Hormone containing contraceptive&#xD;
&#xD;
               3. Intrauterine device with a failure rate &lt; 1% per year&#xD;
&#xD;
               4. Cervical cap or diaphragm with spermicidal agent&#xD;
&#xD;
               5. Tubal sterilization&#xD;
&#xD;
               6. Vasectomy in male partner&#xD;
&#xD;
               7. Sexual abstinence&#xD;
&#xD;
          7. Negative test for drugs of abuse at Screening unless they are currently prescribed&#xD;
&#xD;
          8. Negative human immunodeficiency virus (HIV) antibody screen at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any acute disease or condition being treated by medical therapy (prescription or over&#xD;
             the counter) known to possibly impact hepatic function&#xD;
&#xD;
          2. History of or recent (&lt; 6 weeks) treatment for a chronic condition with a medication&#xD;
             that is known to have hepatotoxic potential.&#xD;
&#xD;
          3. Any significant physical injury or surgical procedure within 6 weeks of Screening&#xD;
&#xD;
          4. Uncontrolled diabetes (hemoglobin A1c [HbA1c] &gt; 9%)&#xD;
&#xD;
          5. Uncontrolled hypertension (systolic blood pressure [SBP] &gt; 180 mmHg on â‰¥ 3 medications&#xD;
             of different classes for blood pressure control)&#xD;
&#xD;
          6. Have received any investigational medication within 30 days or 5 half-lives, whichever&#xD;
             is longer, prior to study dosing&#xD;
&#xD;
          7. Subjects should not have donated blood within 60 days of study entry or plasma within&#xD;
             7 days of study entry. Subjects must also refrain from blood donation from clinic&#xD;
             admission, throughout the study period, and continuing for at least 30 days following&#xD;
             the last dose of study medication.&#xD;
&#xD;
          8. Positive urine drug screen at Screening that is not otherwise explained by a permitted&#xD;
             concomitant medication&#xD;
&#xD;
          9. History of alcoholism in the 6 months prior to Screening&#xD;
&#xD;
         10. Inadequate peripheral venous access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NGM Study Director</last_name>
    <phone>(650) 243-5555</phone>
    <email>ngm282@ngmbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NGM Clinical Study Site 110</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Duggan</last_name>
    </contact>
    <investigator>
      <last_name>Juan C Rondon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site 111</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Brown</last_name>
    </contact>
    <investigator>
      <last_name>Thomas C Marbury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

